* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:1734 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Sinphar Pharmaceutical Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinphar Pharmaceutical Co Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sinphar Pharmaceutical Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Sinphar Pharmaceutical Co's Days Payable falls into.
Sinphar Pharmaceutical Co Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Sinphar Pharmaceutical Co's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinphar Pharmaceutical Co (TPE:1734) has a Days Payable of 42.47 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sinphar Pharmaceutical Co and its competitors. This is near median its historical median of 46.83. Over the past decade, Sinphar Pharmaceutical Co's Days Payable has ranged from 37.71 to 59.91. According to the industry distribution chart, Sinphar Pharmaceutical Co ranks #509 out of 702 companies in the Biotechnology industry, placing it in the top 72.5%.
Is Sinphar Pharmaceutical Co's Days Payable too high?
Sinphar Pharmaceutical Co's current Days Payable of 42.47 is near median its 10-year median of 46.83. Over the past 10 years, this metric has ranged from a low of 37.71 to a high of 59.91. The Biotechnology industry median Days Payable is 113.10. Sinphar Pharmaceutical Co's value of 42.47 is 62.4% below this industry median. Based on the distribution chart, Sinphar Pharmaceutical Co ranks #509 out of 702 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Sinphar Pharmaceutical Co has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sinphar Pharmaceutical Co's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sinphar Pharmaceutical Co ranks #509 out of 702 companies for Days Payable. This places Sinphar Pharmaceutical Co in the lower half of its industry. The industry median Days Payable is 113.10. Sinphar Pharmaceutical Co's value of 42.47 is 62.4% below this benchmark. Historically, Sinphar Pharmaceutical Co's own Days Payable has ranged from 37.71 to 59.91 over the past decade. While the company's 10-year median is 46.83 vs. the industry median of 113.10, Sinphar Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sinphar Pharmaceutical Co's current Days Payable of 42.47 is 62.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sinphar Pharmaceutical Co and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinphar Pharmaceutical Co's current Days Payable is 42.47, which is near median its own 10-year median of 46.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinphar Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Sinphar Pharmaceutical Co (TPE:1734) is currently considered Fairly Valued. The stock's GF Value™ is NT$33.15, compared to a current price of NT$33.60 — trading 1.4% above its estimated fair value. The current Days Payable is 42.47, which is near median its 10-year median of 46.83 and 62.4% below the Biotechnology industry median of 113.10. Sinphar Pharmaceutical Co's overall GF Score™ is 81/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Sinphar Pharmaceutical Co (TPE:1734), the current Days Payable is 42.47 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinphar Pharmaceutical Co (TPE:1734) Overvalued in 2026?
Based on GuruFocus' analysis, Sinphar Pharmaceutical Co stock appears to be overvalued.
The current stock price of NT$33.60 is trading 1.4% above its estimated GF Value™ of NT$33.15.
GuruFocus considers Sinphar Pharmaceutical Co to be Fairly Valued.
Key valuation signals for TPE:1734:
Days Payable: 42.47 (near median its 10-year median of 46.83)
GF Value™: NT$33.15 vs. price of NT$33.60 (1.4% above fair value)
Industry Position: 62.4% below the Biotechnology median (#509 of 702)
No single metric tells the full story. See the TPE:1734 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sinphar Pharmaceutical Co Ltd operates in the pharmaceutical segment. The company mainly engages in the production, processing, and trading of various Chinese medicines, medicinal cosmetics, and nutrients. The company's reportable segments are; Pharmaceuticals which derives key revenue, Healthy food, and others. Geographically, the company generates a majority of its revenue from Taiwan and the rest from China, Vietnam, Indonesia, America, and other regions.
81GF Score
Get the complete analysis for TPE:1734
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1734 has been successfully added to your 
